Metabolism, Pharmacokinetics
Conditions
Brief summary
This study is designed to determined the metabolism, excretion, and substance balance of almonertinib of ADC189. The pharmacokinetic characteristics and safety profile of ADC189 was investigated following a single oral dose (45 mg/100 µCi) in healthy Chinese male participants.
Detailed description
This study adopted a single-center, open, non-randomized, single-dose design. Six to eight healthy Chinese male subjects were planned to be enrolled, and the final aim is to collect all required samples and data from at least 6 subjects. After each subject take a single oral dose of 45 mg (about 100 μCi) \[14C\]ADC189 on Day 1, whole blood, plasma, urine and feces samples were collected at specified time points during the study. The total radioactivity was measured to calculate the ratio of total radioactivity of whole blood to total radioactivity of plasma, pharmacokinetic parameters, recovery rate and excretion pathway data of total radioactivity in whole blood and plasma. Meanwhile, the radioactive metabolite spectrum and structural identification of main metabolites in plasma, urine and feces were performed to obtain the pathway and characteristics of main metabolic elimination of ADC189 in human body, as well as circulating metabolites ≥10% of total radioactivity exposure in plasma.
Interventions
DRUG[(14)C]ADC189
Each subject take a single oral dose of about 45 mg (about 100 μCi) \[(14)C\]ADC189 on Day 1 of the study, and be observed by 504 hours.
Sponsors
Jiaxing AnDiCon Biotech Co.,Ltd
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* 1\. healthy Chinese male subjects within 18 to 45 years old inclusive; * 2\. body weight over 50 Kg, and within a BMI range of 19.0 to 26.0 kg/m2 inclusive; * 3\. has no sperm donation plan, no family planning and voluntarily adopts strict contraceptive methods during the study period and within six months after the completion of the trial; * 4\. able to comprehend and willing to sign an Informed Consent Form (ICF).
Exclusion criteria
* 1\. history or presence of an abnormal ECG; * 2\. participation in more than 1 other radiolabeled investigational study drug trial within 12 months prior to Check-in; * 3\. exposure to significant radiation within 12 months prior to Check-in; * 4\. participation in any other investigational study drug trial; * 5\. use of any prescription medications/products within 14 days prior to Check-in; * 6\. use of any drug that affects drug metabolism enzymes or transporters (P-gp and BCRP) in the 30 days prior to taking the study drug, as detailed in Appendix 5; * 7\. receipt of blood products within 1 month prior to Check-in.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The urinary and fecal recovery of total radioactivity of [(14)C]ADC189 (about 100 μCi) | 504 hours |
| The Area Under the Curve (AUC) of [(14)C]ADC189 and its metabolites | 504 hours |
| The Maximum Plasma Concentration [Cmax] of [(14)C]ADC189 and its metabolites | 504 hours |
| The whole blood and serum concentrations of total radioactivity of [(14)C]ADC189 (about 100 μCi) | 504 hours |
Countries
China
Outcome results
None listed